相关实验视频
Updated: Jun 12, 2025

08:28
Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers
Published on: September 19, 2017
7.9K
作为抗癌剂的本齐米达基小分子向端粒G-四重复和抑制端粒酶酶的抗癌剂
Hemanathan Elango1, Rabindra Nath Das2, Abhijit Saha1
1Department of Chemistry, SRM Institute of Science & Technology, Kattankulathur, Tamil Nadu, 603203, India.
Future medicinal chemistry
|September 24, 2024
概括
西米达衍生物稳定端粒G-四重复基DNA,抑制端粒酶,并通过抑制癌细胞生长显示出作为抗癌剂的潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 端粒对染色体的完整性至关重要,并且与衰老和癌症有关.
- G四复合体是核酸结构,特别是在富含关氨酸的区域,涉及到细胞过程.
- 准G-四复合体提供了选择性抑制癌细胞生长的策略.
研究的目的:
- 审查本齐米达衍生物作为G-四重复稳定剂.
- 探索它们在抗癌药物开发中的潜力.
- 研究它们对端粒酶活性和基因表达的影响.
主要方法:
- 关于G-四重复合联体的最新研究的综述.
- 专注于本齐米达衍生物及其与端粒DNA的相互作用.
- 对抗增殖效应和端粒酶抑制的分析.
主要成果:
- 西米达衍生物有效地稳定了端粒DNA的G-四重复结构.
- 这些化合物对癌细胞表现出抗增殖活性.
- 它们具有影响瘤基因表达和抑制端粒酶的潜力.
结论:
- 西米达衍生物是新型抗癌疗法的有希望的候选者.
- 稳定端粒G-四倍体DNA是癌症治疗的可行策略.
- 对这些连接体的进一步研究可能会导致向癌症药物.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Telomeres and Telomerase
23.2K
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...
23.2K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Replicative Cell Senescence
3.6K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

